Skip to Content

MVASI Dosage

Generic name: BEVACIZUMAB-AWWB 100mg in 4mL
Dosage form: injection, solution

Medically reviewed by Drugs.com. Last updated on Jun 25, 2019.

Important Administration Information

Do not administer MVASI until at least 28 days following surgery and the wound is fully healed.

Metastatic Colorectal Cancer

The recommended dosage when MVASI is administered in combination with intravenous fluorouracil-based chemotherapy is:

  • 5 mg/kg intravenously every 2 weeks in combination with bolus-IFL.
  • 10 mg/kg intravenously every 2 weeks in combination with FOLFOX4.
  • 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line bevacizumab product-containing regimen.

First-Line Non-Squamous Non-Small Cell Lung Cancer

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel.

Recurrent Glioblastoma

The recommended dosage is 10 mg/kg intravenously every 2 weeks.

Metastatic Renal Cell Carcinoma

The recommended dosage is 10 mg/kg intravenously every 2 weeks in combination with interferon-alfa.

Persistent, Recurrent, or Metastatic Cervical Cancer

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with paclitaxel and cisplatin, or in combination with paclitaxel and topotecan.

Dosage Modifications for Adverse Reactions

Table 1 describes dosage modifications for specific adverse reactions [see Warnings and Precautions (5)]. No dose reductions for MVASI are recommended.

Table 1: Dosage Modifications for Adverse Reactions
Adverse Reaction Severity Dosage Modification
Gastrointestinal Perforations and Fistulae [see Warnings and Precautions (5.1)]
  • Gastrointestinal perforation, any grade
  • Tracheoesophageal fistula, any grade
  • Fistula, Grade 4
  • Fistula formation involving any internal organ
Discontinue MVASI
Wound Healing Complications [see Warnings and Precautions (5.2)]
  • Wound healing complications requiring medical intervention
  • Necrotizing fasciitis
Discontinue MVASI
Hemorrhage [see Warnings and Precautions (5.3)]
  • Grade 3 or 4
Discontinue MVASI
  • Recent history of hemoptysis of 1/2 teaspoon (2.5 mL) or more
Withhold MVASI
Thromboembolic Events [see Warnings and Precautions (5.4, 5.5)]
  • Arterial thromboembolism, severe
Discontinue MVASI
  • Venous thromboembolism, Grade 4
Discontinue MVASI
Hypertension [see Warnings and Precautions (5.6)]
  • Hypertensive crisis
  • Hypertensive encephalopathy
Discontinue MVASI
  • Hypertension, severe (such as Grade 3 and above)
Withhold MVASI until controlled with medical management; resume once controlled
Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.7)]
  • Any
Discontinue MVASI
Renal Injury and Proteinuria [see Warnings and Precautions (5.8)]
  • Nephrotic syndrome
Discontinue MVASI
  • Proteinuria greater than or equal to 2 grams per 24 hours in absence of nephrotic syndrome
Withhold MVASI until proteinuria less than 2 grams per 24 hours
Infusion-Related Reactions [see Warnings and Precautions (5.9)]
  • Severe
Discontinue MVASI
  • Clinically significant
Interrupt infusion; resume at a decreased rate of infusion after symptoms resolve
  • Mild, clinically insignificant
Decrease infusion rate
Congestive Heart Failure [see Warnings and Precautions (5.12)] Any Discontinue MVASI

Preparation and Administration

Preparation

  • Use appropriate aseptic technique.
  • Visually inspect vial for particulate matter and discoloration prior to preparation and administration. Discard vial if solution is cloudy, discolored or contains particulate matter.
  • Withdraw necessary amount of MVASI and dilute in a total volume of 100 mL of 0.9% Sodium Chloride Injection, USP. DO NOT ADMINISTER OR MIX WITH DEXTROSE SOLUTION.
  • Discard any unused portion left in a vial, as the product contains no preservatives.
  • Store diluted MVASI solution at 2°C to 8°C (36°F to 46°F) for up to 8 hours.
  • No incompatibilities between MVASI and polyvinylchloride or polyolefin bags have been observed.

Administration

  • Administer as an intravenous infusion.
  • First infusion: Administer infusion over 90 minutes.
  • Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions